HSP90AB1 and central nervous system cancer: In the present study, the pharmacological inhibition of HSP90 with PU-H71 potently depleted pro-survival kinases in patient-derived glioma cells; however, in vivo experiments in our laboratory showed that the drug has limited BBB permeability in in vivo glioma models.